Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed next steps in the evaluation of tildrakizumab for the treatment of psoriasis.
Next investigative targets for the evaluation of tildrakizumab in the treatment of psoriasis will address its efficacy on more sensitive affected areas, such as the scalp, nails, face, and neck, said Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America.
Rozzo served as co-author of 2 studies presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting: "Real-world Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Plaque Psoriasis: Week 28 Interim Analysis of a Phase 4 Study” and “A Phase 4, Real-world Study of Tildrakizumab in Moderate-to-Severe Psoriasis: Week 28 Interim Analysis.”
Transcript
What further investigation is being considered for tildrakizumab in the treatment of psoriasis?
The next steps are to look at various topics that are not only traditionally examined in such patients—for example, scalp psoriasis we have an investigation underway for that, and nails with psoriasis often have effects—but we're also looking at some issues that are frequently of concern to patients and providers that are often not looked at that carefully.
For example, many companies will look at lesions on the head, on the scalp, but they don't necessarily do careful examination of lesions on the face or the neck, which are obviously very important to patients. Nobody wants to have any kind of lesion like that. So, we're taking a careful look at that. And we especially want to look at the patients with the 50% worst disease.
We set the bar very high. We want to see complete clearance, complete elimination of disease activity. So, we try to think of the problems patients face with psoriasis from their view and also from the health care providers' view, because they obviously want their patients to be all better as well.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More